Search QAs

Does EIOPA have, and can it make available, an electronic version of the register of information, the content and template of which are set out in the draft commision implementing standard laying down implementing technical standards with regard to standard templates for the register of information according to Regulation (EU) 2022/2554 of the European Parliament and of the Council?

We understand that in Template 27.01.b. (Man made catastrophe risk - Liability) the “Earned premium last 12 months” should be considered, is this correct?

The first question is: Does the exception in Article 24(3), second subparagraph, apply to travel insurance sold together with a credit card? A credit card is not a payment account as defined in Article 2(3) of Directive 2014/92/EU, but a credit card typically is linked to an underlying payment account. Is the sale of travel insurance together with a credit card therefore covered by the ex-ception, or does the requirement to offer the insurance separately apply? The second question is: Depending on the answer to the first question, to what extent is a de-mand and needs assessment required under Article 20 of the IDD when travel insurance is sold as an inseparable part of a credit card package? We would appreciate EIOPA’s clarification on the application of these provisions in the context described.

What is the intended difference in information and insight for Direct Business for QRT S.04.04 vs S.04.05?

In relation to columns C0110 and C0120, you refer to claims that "have been settled with payment during the reporting year". Should the claims, on which the payment occured during the year, but they are for some reason still OPEN at the year-end (thus they are not fully settled) be also included or not?

Question 2433 clarifies that the non-life lapse risk shall be based on "policies for which discontinuance would result in an increase of technical provisions" (directive text) "before the payments caused by the discontinuance are made" (Q&A clarification). With this clarification, discontinuance of any profitable contract will result in a (short term) increase in the provisions and are thus within scope of the Lapse risk calculation.

We have a question regarding S.37.01 Cell C0320 – Exemptions (included in the Implementing Regulation 2023/894), where we seek clarification of what information is asked for specifically. The cell C0320 makes reference to Article 187 in the delegated regulation, and in its reporting events, EIOPA has also referred to the banking regulation (Article 400 in the Regulation (EU) No 575/2013); We understand this is because both articles/legislations are referred to in the FICOD reporting requirements (Implementing Regulation 2022/2454, template FC.06, cell FC0270).

Is the column "Maximum cover by transaction" (C0150) meant to include only internal reinsurance?

We have read EIOPA’s answer in relation to question #2774, and would like to clarify our understanding in regards to the instructions provided to the template S.36.05 in EU/2023/894. In terms of the overlap mentioned between S.36.01/S.36.02 and S.36.05, is it correctly understood then that the instructions in the “General comments” to QRT S.36.05.01 (“This template shall report the P&L associated to all (significant, very significant and transactions required to be reported in all circumstances) intra-group transactions between entities in the scope of the group supervision or P&L transaction considered as significant or very significant intragroup transactions or transactions required to be reported in all circumstances”) should be read in the following manner: